SK Biopharm Signs Pharmaceutical Supply Contract Worth 1.9 Billion KRW
[Asia Economy Reporter Gong Byung-sun] SK Biopharm announced on the 15th that it has signed a pharmaceutical supply contract worth 1.9 billion KRW with its U.S. local subsidiary, SK Life Science, Inc., for the sale of the new epilepsy treatment drug Cenobamate in the U.S. market.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Insisting on Phone Consultations Only for Hearing-Impaired Clients"... Human Rights Commission Recommends Staff Training for Foundation
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
This corresponds to 7.23% of recent sales revenue.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
